TrialArthritis research & therapy2012

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial.

Brinda Emu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.